Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-27
2009-12-01
Fay, Zohreh A (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C514S913000
Reexamination Certificate
active
07625927
ABSTRACT:
Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
REFERENCES:
patent: 4550022 (1985-10-01), Garabedian et al.
patent: 5049586 (1991-09-01), Ortega et al.
patent: 5620995 (1997-04-01), Weidmann et al.
patent: 5719164 (1998-02-01), Weidmann et al.
patent: 5916898 (1999-06-01), Edwards et al.
patent: 5952378 (1999-09-01), Stjernschantz et al.
patent: 6020350 (2000-02-01), Weidmann et al.
patent: 6093730 (2000-07-01), Weidmann et al.
patent: 6441047 (2002-08-01), DeSantis, Jr.
patent: 2004/0235082 (2004-11-01), Fourney et al.
patent: 2004/0254215 (2004-12-01), Arend et al.
patent: 197 46 287 (1999-04-01), None
patent: 0 661 269 (1995-07-01), None
patent: 0 765 871 (1997-04-01), None
patent: 0 846 685 (1998-06-01), None
patent: 99/21860 (1999-05-01), None
patent: 2004/052284 (2004-06-01), None
patent: 2004/052285 (2004-06-01), None
patent: 2004/108681 (2004-12-01), None
patent: 2005/034929 (2005-04-01), None
Anderson et al., “Effect of Intraocular Pressure on Rapid Axoplasmic Transport in Monkey Optic Nerve”, IOVS, vol. 13(10):771-783, 1974.
Arita et al., “Resolvin E1, An Endogenous Lipid Mediator Derived from Omega-3 Eicosapentaenoic Acid, Protects Against 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis”, PNAS, vol. 102(21):7671-7676, May 2005.
Arjamaa et al., “Oxygen-Dependent Diseases in the Retina: Role of Hypoxia-Inducible Factors”, Experimental Eye Research, vol. 83(3):473-483, Sep. 2006.
Butler, D., “Cheaper Approaches to Flu Divide Researchers”, Nature, vol. 448:976-977, Aug. 2007.
Clark et al., “Ophthalmic Drug Discovery”, Nature Reviews—Drug Discovery, vol. 2(6):448-459, Jun. 2003.
Esquenazi et al., “Topical Combination of NGF and DHA Increases Rabbit Corneal Nerve Regeneration After Photorefractive Keratectomy”, IOVS, vol. 46(9):3121-3127, Sep. 2005.
Fahy et al., “A Comprehensive Classification System for Lipids1”, Journal of Lipid Research, vol. 46:839-861, 2005.
Fiorucci et al., “A B-Oxidation-Resistant Lipoxin A4 Analog Treats Hapten-Induced Colitis by Attenuating Inflammation and Immune Dysfunction,” PNAS, vol. 101(44):15736-15741, Nov. 2004.
Gewirtz et al., “Lipoxin A4 Analogs Attenuate Induction of Intestinal Epithelial Proinflammatory Gene Expression and Reduce the Severity of Dextran Sodium Sulfate-Induced Colitis”, Journal of Immunology, vol. 168(10):5260-5267, 2002.
Gronert et al., “A Role for the Mouse 12/15-Lipoxygenase Pathway in Promoting Epithelial Wound Healing and Host Defense”, Journal of Biological Chemistry, vol. 280(15):15267-15278, 2005.
Guilford et al., “Novel 3-Oxa Lipoxin A4 Analogues with Enhanced Chemical and Metabolic Stability Have Anti-inflammatory Activity in Vivo”, J. Medicinal Chemistry, vol. 47:2157-2165, 2004.
Hashimoto et al., “Long-term activation of c-Fos and c-Jun in Optic Nerve Head Astrocytes in Experimental Ocular Hypertension in Monkeys and After Exposure to Elevated Pressure in Vitro”, Brain Research, vol. 1054(2):103-115, 2005.
Hirsila et al., “Characterization of the Human Prolyl 4-Hydroxylases that Modify the Hypoxia-inducible Factor”, Journal of Biological Chemistry, vol. 278(33):30772-30780, 2003.
Ivan et al., “Biochemical Purification and Pharmacological Inhibition of a Mammalian Prolyl Hydroxylase Acting on Hypoxia-Inducible Factor”, PNAS, vol. 99(21):13459-13464, Oct. 2002.
Kaplan et al., “Signal Transduction by the Neurotophin Receptors”, Current Opinion in Cell Biology, vol. 9:213-221, 1997.
Kuehn et al., “Retinal Ganglion Cell Death in Glaucoma: Mechanisms and Neuroprotective Strategies”, Ophthalmology Clinics of North America, vol. 18(3):383-395, 2005.
Kwong et al, “Expression of Phosphorylated c-Jun N-terminal Protein Kinase (JNK) in Experimental Glaucoma in Rats”, Experimental Eye Research, vol. 82(4):576-582, 2006.
Lee et al., “Glaucoma and its Treatment: A Review”, Am. J. Health System Pharm., vol. 62(7):691-699, 2005.
Lee et al., “Neuronal Apoptosis Linked to EgIN3 Prolyl Hydroxylase and Familial Pheochromocytoma Genes: Development Culling and Cancer”, Cancer Cell, vol. 8(2):155-167, Aug. 2005.
Levy et al., “Expression of BPI (bactericidal/permeability-increasing protein) in Human Mucosal Epithelial”, Biochemical Society Transactions, vol. 31(4):795-800, 2003.
Lewin et al., “Physiology of the Neurotrophins”, Ann. Rev. Neuroscience, vol. 19:289-317, 1996.
Lipscomb et al., “SM-20 Is a Novel Mitochondrial Protein That Causes Caspase-Dependent Cell Death in Nerve Growth Factor-dependent Neurons”, Journal of Biological Chemistry, vol. 276(7):5085-5092, 2001.
Lipscomb et al., “Expression of the SM-20 Gene Promotes Death in Nerve Growth Factor-Dependent Sympathetic Neurons”, Journal Neurochemistry, vol. 73(1):429-432, 1999.
Lotzer et al., “The 5-Lipoxygenase Pathway in Arterial Wall Biology and Atherosclerosis”, Biochimica et Biophysica Acta, vol. 1736(1):30-37, 2005.
Lukiw et al., “A Role for Docosahexaenoic Acid-Derived Neuroprotection D1in Neural Cell Survival and Alzheimer Disease”, Journal of Clinical Investigation, vol. 115(10):2774-2783, Oct. 2005.
Mansour-Robaey et al., “Effects of Ocular Injury and Administration of Brain-Derived Neurotrophic Factor on Survival and Re-growth of Axotomized Retinal Ganglion Cells”, PNAS, vol. 91(5):1632-1636, Mar. 1994.
Meyer-Franke et al., “Characterization of the Signaling Interactions that Promote the Survival and Growth of Developing Retinal Ganglion Cells in Culture”, Neuron, vol. 15(4), 805-819, Oct. 1995.
Mukherjee et al., “Neuroprotection D1: A Docosahexaenoic Acid-Derived Docosatriene Protects Human Retinal Pigment Epithelial Cells From Oxidative Stress”, PNAS, vol. 101(22):8491-8496, Jun. 2004.
Peso et al., “The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of HIF-Proline Hydroxylase Genes in Response to Low Oxygen”, Journal of Biological Chemistry, vol. 278(49):48690-48695, Dec. 2003.
Quigley et al., “The Dynamics and Location of Axonal Transport Blockade by Acute Intraocular Pressure Elevation in Primate Optic Nerve”, IOVS, vol. 15(8):606-616, Aug. 1976.
Quigley et. al., “The Transcription Factor C-Jun is Activated in Retinal Ganglion Cells in Experimental Rat Glaucoma”, Experimental Eye Research, vol. 80(5):663-670, 2005.
Schlingensiepen et al., “The Role of Jun Transcription Factor Expression and Phosphorylation in Neuronal Differentiation, Neuronal Cell Death, and Plastic Adaptations in Vivo”, Cellular & Molecular Neurobiology, vol. 14 (5):487-505, 1994.
Segal R.A., “Selectivity in Neurotrophin Signaling: Theme and Variations”, Annual Review Neuroscience, vol. 26:299-330, 2003.
Sowers et al., “The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients with Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus”, Archives of Internal Medicine, vol. 165(2):161-168, 2005.
Straub et al., “Induction of SM-20 in PC12 Cells Leads to Increased Cytochrome c Levels, Accumulation of Cytochrome c in the Cytosol, and Caspase-Dependent Cell Death”, Journal of Neurochemistry, vol. 85(2):318-328, 2003.
Wallace et al., “Lipoxins in Gastric Mucosal Health and Disease”, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 73(3-4):251-255, 2005.
Wang et al., “Factors Contribution to Neuronal Degenera
Klimko Peter G.
Pang Iok-Hou
Alcon Research, Ltd.
Fay Zohreh A
Flanigan Mark E.
LandOfFree
Method of treating glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4057438